Corporate Update on Vivos Therapeutics, Inc. (VVOS)
Market Performance
On Friday, 23 November 2026, Vivos Therapeutics’ shares fell 4.26 % during a 24‑hour trading period that concluded at 02:22 PM Central Europe time. The stock is currently priced at approximately USD 0.13 on major exchanges, with a market capitalization of USD 4.5 million and a share supply of 13.9 million. In the last 24 hours alone, roughly USD 622.2 thousand of Vivos Therapeutics shares changed hands. Since the close of last month, the company’s share price has declined 14.01 %. The simple moving average over the past 200 days stands at USD 0.81, while the 52‑week high of USD 3.05 was reached on 27 October 2025. The 52‑week low of USD 0.12 occurred on 20 October 2026.
Proxy Statement for the 2026 Annual Meeting
Vivos Therapeutics, Inc. has filed a preliminary proxy statement in preparation for its 2026 annual meeting scheduled for 2 December 2026. The filing outlines ten proposals for shareholder consideration:
- Election of directors
- Advisory vote on executive compensation and its frequency
- Ratification of the auditor
- Proposed reverse stock split to address Nasdaq price‑minimum compliance
- Approval of Nasdaq‑rule related issuances of common stock tied to preferred shares
- Amendment to the 2024 equity incentive plan
- Conversion of the corporation to Nevada law
- Possibility of adjournment
- Voting procedures and record‑keeping
- Contact information for inquiries
The board, chaired by R. Kirk Huntsman, CEO, is presenting a slate of seven directors to be elected. The proxy statement also details the voting process, record‑keeping requirements, and provides contact information for shareholder questions.
Contextual Performance of Peer Shares
In the same 24‑hour window, the following related stocks exhibited varying performance:
- Revitalist Lifestyle And Wel (RVLWF): flat 0 %, trading at USD 0.04, market cap USD 5.4 million.
- Volitionrx (VNRX): flat 0 %, trading at USD 0.17, market cap USD 5 million.
- Twin Vee Powercats (VEEE): down 3.75 %, trading at USD 9.29, market cap USD 5.4 million.
- Aqua Metals (AQMS): down 1.32 %, trading at USD 1.49, market cap USD 5.4 million.
- Cardio Diagnostics (CDIO): up 2.91 %, trading at USD 1.70, market cap USD 5.2 million.
These figures provide a snapshot of sector activity and highlight the relative volatility of Vivos Therapeutics compared to its peers.
Company Overview
Vivos Therapeutics, Inc. is a medical‑technology firm headquartered in Highlands Ranch, United States, that specializes in developing solutions for patients with sleep‑disordered breathing and obstructive sleep apnea. The company’s mission is to revolutionize treatment for sleep‑related respiratory disorders by delivering innovative products that enhance patients’ quality of life. Vivos Therapeutics serves exclusively the United States market and is publicly traded on the Nasdaq stock exchange. Further information and product details can be found at www.vivoslife.com .
